Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.
OBJECTIVE: To assess the feasibility and impact of highly active antiretroviral therapy (HAART) started in vertically HIV-1-infected infants less than 3 months of age. DESIGN: A multicentre, phase I/II, non-randomized, open-label study (PENTA 7). METHODS: Adverse events, plasma HIV-1 RNA, CD4 cell...
Հիմնական հեղինակներ: | Aboulker, J, Babiker, A, Chaix, M, Compagnucci, A, Darbyshire, J, Debré, M, Faye, A, Giaquinto, C, Gibb, D, Harper, L, Saïdi, Y, Walker, A |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
2004
|
Նմանատիպ նյութեր
-
Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial
: Aboulker, J, և այլն
Հրապարակվել է: (2002) -
Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life
: Barbara Laughton, և այլն
Հրապարակվել է: (2019-10-01) -
A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.
: Green, H, և այլն
Հրապարակվել է: (2006) -
Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
: Walker, A, և այլն
Հրապարակվել է: (2010) -
Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution.
: Lewis, J, և այլն
Հրապարակվել է: (2012)